CJC (no DAC)/Ipamorelin 5mg/5mg
Em Estoque e Pronto para Envio dos EUA
Frete GRATIS em pedidos acima de US$200
Checkout seguro via processador de pagamento criptografado
Apenas para Uso em Pesquisa
Estes produtos sao destinados exclusivamente a pesquisa laboratorial e nao se destinam ao uso medico. Nao sao aprovados pela FDA para diagnosticar, tratar, curar ou prevenir qualquer doenca. Ao adquirir, voce certifica que os produtos serao utilizados exclusivamente para pesquisa e nao para consumo humano ou animal.
Bundle / Blend Research
This product contains CJC-1295 (no DAC) + Ipamorelin. Select a tab below to view the full Gold Standard research profile for each component.
Visao Geral
Visao Geral da Pesquisa
CJC-1295 (no DAC), frequently referred to no(a) scientific literature as Modified GRF (1-29) or Mod GRF 1-29, e um(a) sintetico(a) peptide analog of endogenous hormonio do crescimento-releasing hormone (GHRH). It is derivado(a) de the primeiro(a) 29 aminoacidos do(a) native 44-aminoacido GHRH molecule produziu no(a) hypothalamus, representing the biologically ativo(a) fragment responsavel por stimulating hormonio do crescimento (GH) release do(a) anterior pituitary gland.[1][2] O peptideo foi originalmente desenvolvido(a) by ConjuChem Biotechnologies Inc. (Montreal, Canada) as part do(a) CJC-1295 drug development program, onde the tetrasubstituted core peptide served como o(a) precursor para o(a) long-acting DAC-conjugated variant.[4]
The term "tetrasubstituted" refers to four strategic aminoacido substitutions no(a) native GHRH(1-29) sequence: D-Alanine at position 2, Glutamine at position 8, Alanine at position 15, and Leucine at position 27.[2][3] Each substitution serves a specific purpose: position 2 (D-Ala) previne DPP-4 enzymatic cleavage, position 8 (Gln) reduz asparagine rearrangement or amide hidrolise to aspartic acid, position 15 (Ala) aprimora bioactivity, and position 27 (Leu) previne methionine oxidation. These modifications coletivamente extend the meia-vida do(a) mere minutes characteristic of native GHRH to aproximadamente 30 minutes for CJC-1295 (no DAC), dramatically improving biodisponibilidade enquanto preserving ligacao ao receptor characteristics.[1][5]
The "no DAC" designation is criticamente importante para researchers to understand. CJC-1295 with DAC (Drug Affinity Complex) contem an N-epsilon-3-maleimidopropionyl-lysine linker que covalently liga-se a serum albumin, extending the meia-vida to 6–8 days and creating continuous, non-physiological GH estimulacao.[4][8] In contrast, CJC-1295 (no DAC) lacks this conjugation entirely, producing pulsatile GH release que mimics the body's natural circadian rhythm. This pulsatile pattern is therapeutically preferred porque it avoids receptor dessensibilizacao (downregulacao) of GHRH receptors and minimizes efeitos colaterais associado(a) com cronico(a) GH elevation.[5][6] The FDA, in its December 2024 Pharmacy Compounding Advisory Committee briefing, explicitly observado(a) que muitos(as) studies cited sob o(a) name "CJC-1295" actually utilized the DAC variant, and que no published human ensaios clinicos or preclinical efficacy studies exist specifically for CJC-1295 sem DAC.[9]
Research into CJC-1295 (no DAC) focuses on conditions driven by hormonio do crescimento deficiency (GHD) or age-related decline do(a) GH/IGF-1 axis. Key investigacional areas include composicao corporal and muscle hypertrophy (via GH-mediated protein synthesis and IGF-1 estimulacao), lipid metabolismo (GH-facilitou lipolysis and reduziu visceral tecido adiposo), reparo tecidual and injury recovery (sintese de colageno estimulacao via o(a) GH/IGF-1 axis), sleep physiology (GHRH analogs and slow-wave sleep enhancement), and anti-envelhecimento cellular function (restoring youthful GH pulsatility).[6][7][12] It is frequently studied em combinacao com Ipamorelin, a selective GH secretagogue que acts on a complementary receptor (the ghrelin/GHS receptor), for a synergistic effect on GH release.[12]
Forensic and analytical chemistry studies by Henninge et al. (2010) and Hartvig et al. (2014) have confirmou que products marketed as "CJC-1295" no(a) grey market frequently contain the no-DAC variant (Modified GRF 1-29) rather do que the genuine CJC-1295 with DAC, underscoring the importance of precise nomenclature and rigorous analytical verification using RP-HPLC and LC-MS/MS.[1][3][13]
Mecanismo de Acao
Mecanismo de Acao
CJC-1295 (no DAC) functions como um(a) selective GHRH agonista do receptor que liga-se a hormonio do crescimento-releasing hormone receptors (GHRHr) on somatotroph cells no(a) anterior pituitary gland, initiating a cAMP-dependent cascata de sinalizacao que estimula hormonio do crescimento (GH) gene transcricao, synthesis, and pulsatile secretion.[7][8]
Primary Receptor Target & Binding Characteristics
| Property | Detail | Evidence |
|---|---|---|
| Primary Target | Growth Hormone-Releasing Hormone Receptor (GHRHr) on anterior pituitary somatotrophs | Teichman et al. (2006); Alba et al. (2006)[8] |
| Receptor Class | Class B1 (secretin family) G protein-coupled receptor (GPCR) | Established GHRH receptor pharmacology[7] |
| Binding Affinity | High affinity; mimics native GHRH structure with aprimorou stability from tetrasubstitution | Jetté et al. (2005)[4] |
| Binding Reversibility | Reversible binding; crucial for maintaining physiological balance and preventing GH axis overestimulacao | Pharmacokinetic profile[5] |
| Half-Life | ~30 minutes (vs. minutes for native GHRH; vs. 6–8 days for CJC-1295 with DAC) | Soule et al. (1994); Henninge et al. (2010)[2][1] |
| Selectivity | Highly selective for GHRHr on pituitary somatotrophs; possible low-level cross-reactivity dentro do(a) secretin receptor family | 86% homology with endogenous GHRH[7] |
| DPP-4 Resistance | D-Alanine at position 2 previne dipeptidyl peptidase-4 cleavage que rapidly degrades native GHRH | Jetté et al. (2005); Soule et al. (1994)[4][2] |
Downstream Signaling Cascade
| Step | Event | Molecular Detail |
|---|---|---|
| 1. Receptor Binding | CJC-1295 (no DAC) binds GHRHr on somatotroph cell surface | High-affinity, reversible "lock-and-key" interaction mimicking native GHRH[7] |
| 2. G-Protein Activation | Ligand-receptor interaction ativa stimulatory G-proteins (Gs) | Gsα subunit dissociates and ativa downstream effectors[7] |
| 3. cAMP Production | Gs ativa adenylyl cyclase; ATP is converted to cyclic AMP (cAMP) | Intracellular cAMP levels increase significantly (dose-dependente)[7][14] |
| 4. PKA Activation | Elevated cAMP ativa Protein Kinase A (PKA) fosforilacao cascades | PKA phosphorylates transcricao factors incluindo CREB[7] |
| 5. GH Gene Transcription | PKA cascade estimula GH gene transcricao and protein synthesis in somatotrophs | Increased GH mRNA and total pituitary RNA[7][8] |
| 6. Pulsatile GH Secretion | GH is released in a physiological pulse from anterior pituitary | ~30 min meia-vida produz pulsatile (not continuous) GH release[5][6] |
| 7. IGF-1 Stimulation | Released GH estimula the liver to produce Insulin-like Growth Factor-1 (IGF-1) | GH/IGF-1 axis ativacao drives downstream anabolic effects[8] |
Alternative Signaling Pathways
While the Gs/cAMP/PKA cascade is o(a) principal via de sinalizacao, CJC-1295 (no DAC) tambem pode engage the MAPK (mitogen-ativou protein kinase) and PI3K/Akt pathways, que contribute to anabolic effects (protein synthesis via mTOR), anti-apoptotico(a) signaling, and cellular proliferacao.[7]
Cellular and Tissue-Level Effects
| Effect | Detail | Evidence |
|---|---|---|
| Somatotroph Proliferation | Stimulates proliferacao of pituitary somatotroph cells; aumenta total pituitary RNA and GH mRNA | Alba et al. (2006) (DAC variant)[8] |
| GH/IGF-1 Axis | Stimulates pulsatile GH release; liver produz IGF-1; dose-dependente GH and IGF-1 elevation | Teichman et al. (2006) (DAC variant)[8] |
| Lipolysis | GH promove fat breakdown via hormone-sensitive lipase ativacao; inibe lipogenesis | GH/IGF-1 axis pharmacology[7] |
| Protein Synthesis | Enhances muscle protein synthesis via mTOR pathway ativacao downstream of GH/IGF-1 | GH secretagogue literature[12] |
| Tissue Repair | Accelerates cicatrizacao de feridas and connective reparo tecidual through sintese de colageno estimulacao | GH/IGF-1 axis regenerative properties[12] |
| DNA Damage (Pituitary) | Intense cAMP estimulacao by CJC-1295 in mouse pituitary cells induziu DNA damage (H2AX fosforilacao and comet assays) | Ben-Shlomo et al. (2020) (likely DAC variant)[14] |
Comparison: CJC-1295 No DAC vs. Related Compounds
| Parametro | CJC-1295 No DAC (Mod GRF 1-29) | CJC-1295 With DAC | Native GHRH(1-29) / Sermorelin |
|---|---|---|---|
| Half-Life | ~30 minutes | 6–8 days | Minutes |
| GH Release Pattern | Pulsatile (physiological) | Continuous (non-physiological) | Pulsatile (very brief) |
| DPP-4 Resistance | Yes (D-Ala² substitution) | Yes (D-Ala² substitution) | No (rapidly cleaved) |
| Albumin Binding | None | Covalent (via MPA-Lys linker) | None |
| Receptor Desensibilizacao Risk | Low (pulsatile depuracao) | Higher (chronic estimulacao) | Low (too brief to cause) |
| Clinical Trials | None identificado(a) for this specific compound | Phase I/II completed (Teichman 2006; Ionescu 2006) | aprovado(a) pela FDA (as Sermorelin, discontinued) |
Aplicacoes de Pesquisa
Aplicacoes de Pesquisa
CJC-1295 (no DAC) is utilized in laboratory research to investigate o efeitos of pulsatile GHRH receptor estimulacao no(a) GH/IGF-1 axis across 5+ research domains. It is importante to note que the FDA has identificado(a) no published ensaios clinicos or preclinical efficacy studies specific to CJC-1295 sem DAC; the aplicacao em pesquisas below reflect the broader GHRH analog literature e o(a) known pharmacology do(a) GH/IGF-1 axis.[9]
Application Areas
- Body Composition & Muscle Hypertrophy — Research indica que GHRH analog-estimulou GH release promove protein synthesis and aumenta lean muscle mass through IGF-1 estimulacao. CJC-1295 (no DAC) is frequently studied no contexto de sarcopenia (age-related muscle loss) to determine if pulsatile GHRH estimulacao can preserve muscle tissue and strength in aging populations.[6][12]
- Lipid Metabolism & Weight Management — Studies suggest que upregulacao of GH secretion facilita lipolysis (fat breakdown) and inibe lipogenesis. Researchers investigate the utility of GHRH analogs in models of obesidade and metabolic syndrome, focusing on melhorou energy expenditure and reduction of visceral tecido adiposo.[6][12]
- Tissue Repair & Injury Recovery — Due para o(a) regenerative properties do(a) GH/IGF-1 axis, este peptideo is researched for its potential para acelerar the healing of connective tissues, incluindo tendons and ligaments. It is hypothesized para aprimorar sintese de colageno and cellular repair mechanisms apos agudo(a) injury or surgery.[6]
- Sleep Physiology — Growth hormone secretion is intimately linked with slow-wave sleep (SWS). Research explores the potential of GHRH analogs to deepen sleep cycles and improve restorative sleep states, as GHRH activity is necessary to initiate and maintain the deepest stages of non-REM sleep.[6]
- Anti-Aging & Cellular Function — Investigational uses focus on o peptideo's ability para restaurar "youthful" GH pulsatility in aging populations, potentially mitigating physiological declines associado(a) com the somatopause, incluindo reduziu skin elasticity, densidade mineral ossea loss, and cognitive function decline.[6][12]
Evidence Summary by Application
| Application | Mecanismo | Evidence Level | Key References |
|---|---|---|---|
| Muscle Hypertrophy / Sarcopenia | GH → IGF-1 → mTOR → protein synthesis | Preclinical (DAC variant); theoretical for no-DAC | Sinha et al. (2020)[12] |
| Lipid Metabolism / Obesity | GH → hormone-sensitive lipase → lipolysis; inibiu lipogenesis | Preclinical (DAC variant); theoretical for no-DAC | Sigalos & Pastuszak (2018)[7] |
| Tissue Repair / Connective Tissue | GH/IGF-1 → sintese de colageno estimulacao | Theoretical; based on GH/IGF-1 axis physiology | GH axis pharmacology[6] |
| Sleep Enhancement | GHRH signaling → slow-wave sleep induction and maintenance | Theoretical; based on GHRH/SWS relationship | GHRH sleep physiology literature[6] |
| Anti-Aging / Somatopause | Restoration of pulsatile GH secretion; IGF-1 normalization | Theoretical; based on age-related GH decline | Sinha et al. (2020)[12] |
| Pituitary Biology / DNA Damage | cAMP estimulacao → H2AX fosforilacao → DNA damage in somatotrophs | Preclinical in vitro/in vivo (likely DAC variant) | Ben-Shlomo et al. (2020)[14] |
Synergistic Combination Research
CJC-1295 (no DAC) is frequently studied em combinacao com Ipamorelin, a selective hormonio do crescimento secretagogue que acts no(a) ghrelin/GHS receptor (a complementary pathway to GHRH). The rationale is que simultaneous GHRH receptor ativacao (via CJC-1295 no DAC) and GHS receptor ativacao (via Ipamorelin) produce a synergistic amplification of GH release beyond what qualquer compound achieves alone.[12]
Analytical & Forensic Applications
CJC-1295 (no DAC) has been a subject of forensic and anti-doping research. Henninge et al. (2010) and Hartvig et al. (2014) developed LC-MS/MS methods to identify Modified GRF 1-29 in seized pharmaceutical preparations, confirming its widespread distribuicao no(a) grey market. These analytical methods also serve como o(a) basis for WADA anti-doping testing protocols.[1][3][13]
Caracteristicas Bioquimicas
| Propriedade | Valor |
|---|---|
| Molecular Formula | C₁₅₂H₂₅₂N₄₄O₄₂ |
| Molecular Weight | 3367.95 g/mol |
| CAS Number | 863288-34-0 |
| PubChem CID | 56841945 |
| Sequence (1-Letter) | Y-a-D-A-I-F-T-Q-S-Y-R-K-V-L-A-Q-L-S-A-R-K-L-L-Q-D-I-L-S-R-NH₂ (a = D-Alanine) |
| Sequence (3-Letter) | Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂ |
| Structure | 29-aminoacido linear peptide; tetrasubstituted analog of GHRH(1-29) with D-Ala², Gln⁸, Ala¹⁵, Leu²⁷ substitutions; C-terminal amide; lacks DAC (Drug Affinity Complex) moiety |
| Origin | Synthetic analog of human Growth Hormone-Releasing Hormone (GHRH) fragment 1-29, tambem conhecido(a) como Sermorelin. Desenvolvido(a) por ConjuChem Biotechnologies Inc. (Montreal, Canada) |
| Classification | GHRH Analog / Growth Hormone Secretagogue / Research Peptide |
| Half-Life | Aproximadamente 30 minutes (vs. 6–8 days for CJC-1295 with DAC; vs. minutes for native GHRH) |
| Bioavailability | Subcutaneous injection; resistant to DPP-4 enzymatic degradacao; rapidly cleared from bloodstream |
Identifiers
| Purity Standard | |
|---|---|
| Synonyms | |
| Alternate CAS | |
| Monoisotopic Mass | |
| IUPAC Name |
Resumo da Pesquisa Pre-clinica
Resumo da Pesquisa
Clinical & Preclinical Data Status
De acordo com a comprehensive FDA evaluation prepared para o(a) Pharmacy Compounding Advisory Committee (December 2024), there are no published human ensaios clinicos and no preclinical efficacy or toxicity studies specifically for CJC-1295 sem DAC (Modified GRF 1-29). All prominent ensaios clinicos associado(a) com the name "CJC-1295" in medical literature were conducted using the DAC variant, que is pharmacokinetically distinct due to its albumin-binding Drug Affinity Complex.[9][10]
Key Studies on CJC-1295 (DAC Variant) — Often Misatribuido(a) a No-DAC
| Estudo | Modelo | Principais Achados | Ref |
|---|---|---|---|
| Teichman et al. (2006) J Clin Endocrinol Metab | Healthy human adults; 30–250 mcg/kg SC; single or weekly/biweekly doses | Dose-dependent aumenta in mean plasma GH (2–10-fold for ≥6 days) and IGF-1 (1.5–3-fold for 9–11 days). Half-life 5.8–8.1 days. Note: DAC variant, not applicable to no-DAC. | [8] |
| Ionescu & Frohman (2006) J Clin Endocrinol Metab | Healthy human adults; CJC-1295 with DAC | Confirmed que pulsatile GH secretion persists during continuous estimulacao by CJC-1295 (DAC). Note: DAC variant. | [15] |
| Jetté et al. (2005) Endocrinology | Sprague-Dawley rats; 1 µmol/kg SC | Described synthesis of tetrasubstituted GHRH core and DAC conjugation. Demonstrated GH elevation with meia-vida >72 hours. Note: DAC variant. | [4] |
| Alba et al. (2006) Am J Physiol | GHRH camundongos knockout; 2 µg/mouse daily | Normalized growth; aumentou body length and lean mass; aumentou pituitary GH mRNA and somatotroph proliferacao. Note: DAC variant. | [8] |
| Ben-Shlomo et al. (2020) J Clin Invest | C57BL/6 mice and primary pituitary cultures; 10–50 ng/mL in vitro | Intense cAMP estimulacao induziu DNA damage in somatotrophs (H2AX fosforilacao, comet assays). Increased GH levels and pituitary weight in vivo. Note: Likely DAC variant per FDA assessment. | [14] |
Studies Specific to CJC-1295 No DAC (Analytical/Forensic Only)
| Estudo | Context | Principais Achados | Ref |
|---|---|---|---|
| Henninge et al. (2010) Drug Test Anal | Norwegian Doping Control Laboratory; seized pharmaceutical preparations | Identified Modified GRF 1-29 (CJC-1295 sem DAC) in seized products using mass spectrometry. Confirmed widespread distribuicao of no-DAC variant mislabeled as CJC-1295. | [1] |
| Hartvig et al. (2014) Scand J Forensic Sci | Danish authorities; doping compounds confiscated 2007–2013 | Identified CJC-1295 (no DAC) among confiscated peptide preparations. No therapeutic efficacy or safety data gerou. | [3] |
| Fabresse et al. (2017) Toxicol Anal Clin | LC-HRMS/MS identification of CJC-1295 analogs | Developed high-resolution mass spectrometric methods for identifying CJC-1295 peptide analogs in analytical chemistry settings. | [13] |
FDA Assessment Summary (December 2024)
| Category | FDA Finding for CJC-1295 No DAC |
|---|---|
| Clinical Trials | None identificado(a). No Phase I, II, or III trials for CJC-1295 (free base) or CJC-1295 acetate.[9] |
| Preclinical Pharmacology | None identificado(a). No nonclinical pharmacological studies for this specific substance.[9] |
| Preclinical Toxicity | None identificado(a). No agudo(a) toxicity, repeat-dose toxicity, genotoxicity, developmental/reproductive toxicity, or carcinogenicity studies.[9] |
| Perfil de Seguranca | Unknown in humans. Potential risks include immunogenicity and injection site reactions based on peptide characteristics.[9] |
| Regulatory Classification | Categoria 2. Significant safety risks or insufficient evidence; restricted from pharmacy manipulacao.[9][10] |
Dosage Overview (From Literature & Clinical Practice)
| Setting | Dose | Route / Schedule | Notes |
|---|---|---|---|
| In Vitro (pituitary cultures) | 10–50 ng/mL | Cell culture | Ben-Shlomo et al. (2020); likely DAC variant[14] |
| Animal (rats — DAC variant) | 1 µmol/kg SC | Subcutaneous injection | Jetté et al. (2005)[4] |
| Animal (mice — DAC variant) | 2 µg/mouse daily | Subcutaneous injection | Alba et al. (2006)[8] |
| Human (DAC variant) | 30–250 mcg/kg | SC; single or weekly/biweekly | Teichman et al. (2006)[8] |
| Human (no-DAC; clinical practice) | 100–300 mcg | SC; 1–3x daily or 5 days/week | Anecdotal protocols; not derivado(a) de ensaios clinicos |
Safety Considerations
| Parametro | Finding |
|---|---|
| Clinical Safety Data | No submitted or identificado(a) clinical safety studies for CJC-1295 (free base) or acetate[9] |
| Preclinical Toxicity Data | No nonclinical toxicity studies (acute, repeat-dose, genotoxicity) identificado(a)[9] |
| Immunogenicity | Theoretical risk of antibody formation; 86% homology with endogenous GHRH[9] |
| Reported Adverse Effects (Anecdotal) | Injection site reactions, flushing, headache, transient hipotensao, water retention[12] |
| Contraindications (General GHRH Analog) | Active malignancy (GH/IGF-1 may promote tumor growth), pregnancy/breastfeeding, hypersensitivity[7] |
| DAC Variant Safety Note | CJC-1295 with DAC was discontinued during Phase 2 trials after a subject death (atribuido(a) a underlying coronary artery disease, not the drug); no such event linked para o(a) no-DAC variant[7] |
Aviso Importante
Este produto é vendido estritamente apenas para pesquisa in vitro e uso laboratorial. Os produtos oferecidos neste site são fornecidos apenas para estudos in vitro. Estudos in vitro (do latim: em vidro) são realizados fora do corpo. Estes produtos não são medicamentos ou fármacos e não foram aprovados pelo FDA dos EUA para prevenir, tratar ou curar qualquer condição médica, enfermidade ou doença. A introdução corporal de qualquer tipo em humanos ou animais é estritamente proibida por lei.
Sobre Este Perfil de Pesquisa
Este perfil de pesquisa foi compilado a partir de fontes revisadas por pares, incluindo o New England Journal of Medicine, The Lancet e documentos regulatórios. TODOS OS ARTIGOS E INFORMAÇÕES SOBRE PRODUTOS FORNECIDOS NESTE SITE SÃO APENAS PARA FINS INFORMATIVOS E EDUCACIONAIS.
Autores e Atribuicao
✍️ Article Author
Lucie Jetté, PhD
Lucie Jetté, PhD, was a lead researcher at ConjuChem Biotechnologies Inc. (Montreal, Canada), the company que developed the CJC-1295 peptide class. She and her team synthesized the tetrasubstituted hormonio do crescimento-releasing hormone (GHRH) analog conhecido(a) como Modified GRF (1-29), que serves como o(a) core peptide for ambos(as) CJC-1295 (no DAC) and CJC-1295 (with DAC). Her foundational 2005 paper in Endocrinology described the modificacoes estruturais (tetrasubstitution at positions 2, 8, 15, and 27) que grant o peptideo resistance to DPP-4 enzymatic degradacao, and caracterizado(a) the Drug Affinity Complex (DAC) albumin-binding mechanism projetado(a) para extend o peptideo's meia-vida. This work estabeleceu the pharmacological foundation for all subsequente CJC-1295 research, incluindo the ensaios clinicos conducted by Teichman et al. (2006). Her key publication is "Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor no(a) Anterior Pituitary in Rats: Identification of CJC-1295 como um(a) Long-Lasting GRF Analog" (2005, Endocrinology). Lucie Jetté is being referenced as one do(a) leading scientists envolveu in CJC-1295 (no DAC) research. De forma alguma este(a) médico(a)/cientista endossa ou defende a compra, venda ou uso deste produto por qualquer motivo. Não existe afiliação ou relação, implícita ou de outra forma, entre a Pure US Peptide e este(a) médico(a).
🎓 Scientific Journal Author
Lawrence A. Frohman, MD
Lawrence A. Frohman, MD (1935–2018), was a distinguished neuro-endocrinologist and one do(a) foremost authorities on hormonio do crescimento-releasing hormone (GHRH) physiology and pharmacology. He served como o(a) Edmund F. Foley Professor and Chairman do(a) Department of Medicine no(a) University of Illinois College of Medicine in Chicago (1992–2001), and previamente directed the Division of Endocrinology and Metabolism no(a) University of Cincinnati (1981–1992). His extensive career spanned foundational research on GHRH discovery, regulacao, and clinical applications. As a senior investigator no(a) landmark Teichman et al. (2006) and Ionescu & Frohman (2006) ensaios clinicos, he estabeleceu a dose-dependente pharmacokinetic and pharmacodynamic profile of CJC-1295, demonstrating sustained GH and IGF-1 elevation in adultos saudaveis. His key publications include "Prolonged estimulacao of hormonio do crescimento (GH) and insulin-like fator de crescimento I secretion by CJC-1295" (2006, J Clin Endocrinol Metab) and "Pulsatile secretion of hormonio do crescimento persists during continuous estimulacao by CJC-1295" (2006, J Clin Endocrinol Metab). Lawrence A. Frohman is being referenced as one do(a) leading scientists envolveu in CJC-1295 (no DAC) research. De forma alguma este(a) médico(a)/cientista endossa ou defende a compra, venda ou uso deste produto por qualquer motivo. Não existe afiliação ou relação, implícita ou de outra forma, entre a Pure US Peptide e este(a) médico(a).
🔬 Contributing Researcher
Anat Ben-Shlomo, MD
Anat Ben-Shlomo, MD, e um(a) endocrinologist and researcher at Cedars-Sinai Medical Center (Los Angeles, California) e um(a) member do(a) Melmed Research Lab, one do(a) world's preeminent pituitary grupo de pesquisas. She earned her medical degree from Tel Aviv University and specializes no(a) study of genomic changes underlying o desenvolvimento and progression of pituitary tumors, particularmente hormonio do crescimento-secreting somatotroph adenomas que lead to acromegaly. Her landmark 2020 study in The Journal of Clinical Investigation demonstrated que intense cAMP estimulacao by CJC-1295 in mouse pituitary cells induziu DNA damage, as medido(a) by H2AX fosforilacao and comet assays. This work revelou um(a) critico(a) link between GHRH receptor-mediated secretory activity and cellular stress in somatotrophs, showing que somatic copy number alterations (SCNAs) rather do que genetic mutations are hallmarks of these tumors. Her key publication is "DNA damage and hormonio do crescimento hypersecretion in pituitary somatotroph adenomas" (2020, The Journal of Clinical Investigation). Anat Ben-Shlomo is being referenced as one do(a) leading scientists envolveu in CJC-1295 (no DAC) research. De forma alguma este(a) médico(a)/cientista endossa ou defende a compra, venda ou uso deste produto por qualquer motivo. Não existe afiliação ou relação, implícita ou de outra forma, entre a Pure US Peptide e este(a) médico(a).
Citacoes Referenciadas
Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Testing and Analysis, 2(11-12), 647-650, 2010.
DOISoule S, King JA, Millar RP. Incorporation of D-Ala2 in hormonio do crescimento-releasing hormone-(1-29)-NH2 aumenta the meia-vida and diminui metabolic depuracao in normal men. The Journal of Clinical Endocrinology and Metabolism, 79(4), 1208-1211, 1994.
DOIHartvig RA, Holm NB, Dalsgaard PW, Reitzel LA, Müller IB, Linnet K. Identification of peptide and protein doping related drug compounds confiscated in Denmark between 2007-2013. Scandinavian Journal of Forensic Science, 20(2), 42-49, 2014.
DOIJetté L, et al. Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor no(a) Anterior Pituitary in Rats: Identification of CJC-1295 como um(a) Long-Lasting GRF Analog. Endocrinology, 146(7), 3052-3058, 2005.
DOILance VA, Murphy WA, Sueiras-Diaz J, Coy DH. Super-active analogs of hormonio do crescimento-releasing factor (1-29)-amide. Biochemical and Biophysical Research Communications, 119(1), 265-272, 1984.
DOIVan Hout MC, Hearne E. Netnography of Female Use do(a) Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance Use & Misuse, 51(1), 73-84, 2016.
PubMedSigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sexual Medicine Reviews, 6(1), 45-53, 2018.
PubMedTeichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged estimulacao of hormonio do crescimento (GH) and insulin-like fator de crescimento I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in adultos saudaveis. The Journal of Clinical Endocrinology & Metabolism, 91(3), 799-805, 2006.
DOIFood and Drug Administration. FDA Evaluation of CJC-1295 Related Substancia Farmaceutica a Granels. FDA Briefing Document: Pharmacy Compounding Advisory Committee (PCAC) Meeting, December 4, 2024.
FDA.govFood and Drug Administration. Final Summary Minutes do(a) Pharmacy Compounding Advisory Committee Meeting. Center for Drug Evaluation and Research, December 4, 2024.
FDA.govWorld Anti-Doping Agency. The 2024 Lista de Substancias Proibidas: International Standard. World Anti-Doping Code, 2024.
SourceSinha DK, Balasubramanian A, Tatem AJ, Kovac JR, Pastuszak AW, Lipshultz LI. Beyond the androgen receptor: the role of hormonio do crescimento secretagogues no(a) modern management of composicao corporal in hypogonadal males. Translational Andrology and Urology, 9(Suppl 2), S149-S159, 2020.
PubMedFabresse N, Grassin-Delyle S, Etting I, Alvarez JC. Identification of a GHRH peptide analogue, the CJC-1295, using LC-HRMS/MS. Toxicologie Analytique et Clinique, 29(2), 205-211, 2017.
DOIBen-Shlomo A, et al. DNA damage and hormonio do crescimento hypersecretion in pituitary somatotroph adenomas. The Journal of Clinical Investigation, 130(11), 5738-5755, 2020.
SourceIonescu M, Frohman LA. Pulsatile secretion of hormonio do crescimento (GH) persists during continuous estimulacao by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of Clinical Endocrinology & Metabolism, 91(12), 4792-4797, 2006.
DOIMemdouh S, Gavrilović I, Ng K, Cowan D, Abbate V. Advances no(a) detection of hormonio do crescimento releasing hormone synthetic analogs. Drug Testing and Analysis, 13(11-12), 1871-1887, 2021.
DOIArmazenamento e Manuseio
Summary
Liofilizado: -20°C (longo prazo) ou 2–8°C (curto prazo); Reconstituído: 2–8°C, use within 14–28 dias; evite ciclos de congelamento-descongelamento.
Pó Liofilizado
Store at -20°C for estabilidade a longo prazo. The liofilizado form is estavel at refrigerated temperatures (2–8°C) or even room temperature for shorter periods but deve ser kept sealed, away from moisture and direto(a) light for optimal preservation.
Solução Reconstituída
Reconstitua com agua bacteriostatica (preferred for multi-use) or sterile water for injection. Uma vez reconstituído, refrigerate at 2–8°C and use dentro de 14–28 days depending no(a) solvent used and storage conditions. Bacteriostatic water generally allows longer storage comparado(a) a sterile water.
Manuseio
White to off-white liofilizado powder. When reconstituting, inject the solvent slowly down the side do(a) vial and agite suavemente em movimentos circulares — do NOT shake, as this may damage o peptideo structure. Purity: ≥98% by RP-HPLC. Identity: LC-MS/MS (~3367.95 Da). The tetrasubstitution modifications provide resistance to DPP-4 enzymatic degradacao, extending functional meia-vida to aproximadamente 30 minutes do(a) mere minutes characteristic of native GHRH.
Aviso de Uso em Pesquisa
For Research Use Only (RUO). This product is intended solely for in-vitro research and laboratory experimentation. It is not a drug, food, cosmetic, or medical device and has not been approved by the FDA for any human or veterinary use. It must not be used for therapeutic, diagnostic, or any other non-research purpose. Pure US Peptide does not condone or encourage the use of this product for anything other than strictly defined research applications. Users assume full responsibility for compliance with all applicable regulations and guidelines.
Certificado de Analise
Every batch is strictly tested by accredited third-party laboratories (ISO 17025) to ensure 99%+ purity.
Latest Lab Report
Compostos de Pesquisa Relacionados
Tesamorelin/Ipamorelin Blend 11mg/6mg
Tesamorelin 10mg + Ipamorelin 10mg Bundle
Tesamorelin
20mg